Drugs / N-acetyl-aspartyl-glutamate
N-acetyl-aspartyl-glutamate
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT00357019 | Apr 2001 → Oct 2002 | vernal keratoconjunctivitis | Laboratoires Thea | Completed | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | N-acetyl-aspartyl-glutamate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00357019 ↗ |
| Known as | NAAGA | “Twenty-three VKC patients were randomised and treated bilaterally for 28 days with N-acetyl-aspartyl-glutamate (NAAGA) or levocabastine (LEVO) eye-drops.” PMID 17585003 ↗ Jun 2007 |
| Known as | NAAXIA Sine | “N-acetyl-aspartyl-glutamate (NAAXIA Sine)” NCT00357019 ↗ |
| Route | Topical | “N-acetyl-aspartyl-glutamate (NAAGA) or levocabastine (LEVO) eye-drops” PMID 17585003 ↗ Jun 2007 |